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OBJECTIVEdWe aimed to identify factors that are independently associated with the met-
abolic clearance rate of insulin (MCRI) and to examine the association of MCRI with incident type
2 diabetes in nondiabetic Hispanics and African Americans.
RESEARCH DESIGN ANDMETHODSdWe investigated 1,116 participants in the In-
sulin Resistance Atherosclerosis Study (IRAS) Family Study with baseline examinations from
2000 to 2002 and follow-up examinations from 2005 to 2006. Insulin sensitivity (SI), acute
insulin response (AIR), and MCRI were determined at baseline from frequently sampled intra-
venous glucose tolerance tests. MCRI was calculated as the ratio of the insulin dose over the
incremental area under the curve of insulin. Incident diabetes was defined as fasting glucose
$126 mg/dL or antidiabetic medication use by self-report.
RESULTSdWe observed that SI and HDL cholesterol were independent positive correlates of
MCRI, whereas fasting insulin, fasting glucose, subcutaneous adipose tissue, visceral adipose
tissue, and AIR were independent negative correlates (all P , 0.05) at baseline. After 5 years of
follow-up, 71 (6.4%) participants developed type 2 diabetes. Lower MCRI was associated with a
higher risk of incident diabetes after adjusting for demographics, lifestyle factors, HDL choles-
terol, indexes of obesity and adiposity, and insulin secretion (odds ratio 2.01 [95% CI 1.30–
3.10], P = 0.0064, per one-SD decrease in loge-transformed MCRI).
CONCLUSIONSdOur data showed that lower MCRI predicts the incidence of type 2 di-
abetes.
Diabetes Care 36:901–907, 2013
Insulin clearance is an integral compo-nent of insulin metabolism, as it regu-lates the cellular response to the
hormone by decreasing insulin availabil-
ity and mediates certain aspects of insulin
action (1). The liver is the primary site of
insulin clearance. Approximately 80% of
endogenous insulin is removed by the
liver, and the remainder is cleared by the
kidneys and muscles (2). Clearance rates
for insulin decrease in glucose intolerance
(3), obesity (4), in particular abdominal
obesity (5), hypertension (6), hepatic cir-
rhosis (7), and nonalcoholic fatty liver
disease (8).
Although the plasma concentration of
insulin is largely determined by its rate of
secretion and clearance, existing evidence
suggests that increased insulin resistance
is associated with reduced insulin clear-
ance (9–12). Reduced insulin clearance
has important physiological functions;
for example, animal models have shown
that decreased insulin clearance serves
as a compensatorymechanism to preserve
b-cell function and to maintain periph-
eral insulin levels in the states of insulin
resistance (13,14). In addition, insulin
clearance has been found to be a highly
heritable trait in Mexican Americans, and
specific haplotypes in the AMPD1 gene
were associated with variation in insulin
clearance (15).
Despite its potential role in the etiol-
ogy of diabetes, little is known about the
factors that are independently associated
with decreased insulin clearance. In ad-
dition, no previous study has investigated
whether decreased insulin clearance pre-
dicts the risk of type 2 diabetes. In this
study, we aimed to identify demographic
and metabolic factors that are indepen-
dently associated with the metabolic
clearance rate of insulin (MCRI), and to
examine its association with the 5-year
risk of incident type 2 diabetes, using the
data from a large, well-characterized co-
hort of Hispanics and African Americans
with direct measurements of insulin me-
tabolism (secretion, sensitivity, and clear-
ance) and adipose tissue (visceral and
subcutaneous) in the Insulin Resistance
Atherosclerosis Study (IRAS) Family
Study.
RESEARCH DESIGN AND
METHODSdThe study population
consisted of participants in the IRAS
Family Study, a family-based study de-
signed to explore how genetics contribute
to visceral adiposity and insulin resistance
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among Hispanics and African Americans.
In 2000–2002, large families were recruited
at study centers in San Antonio, Texas (His-
panics), San Luis Valley, Colorado (Hispan-
ics), and Los Angeles, California (African
Americans), with probands identified
from the parent study (IRAS) and the
general population. Recruitment was
based on family size, rather than disease
status (16). Of the 1,856 participants
who attended baseline examinations,
1,427 (77%) returned for the 5-year
follow-up between 2005 and 2006. Par-
ticipants who did not return for follow-
up were more likely to be male and had
slightly lower levels of subcutaneous ad-
ipose tissue (SAT) and visceral adipose
tissue (VAT) and higher values for the in-
sulin sensitivity index (SI) (17). The in-
stitutional review boards approved the
study protocol, and all participants pro-
vided written informed consent.
Participants provided a fasting blood
draw at each examination. Plasma insulin
was measured by dextran-charcoal radio-
immunoassay (18). Plasma glucose was
determined on an autoanalyzer using the
glucose oxidase method. Prevalent diabe-
tes at baseline and incident diabetes at
follow-up were defined as fasting glucose
$126 mg/dL or use of antidiabetic med-
ications by self-report. Impaired fasting
glucose was defined as fasting plasma glu-
cose between 100 and 126 mg/dL. Lipids,
including triglycerides (TGs) and HDL
cholesterol, were measured using stan-
dardized laboratory procedures (17). Al-
anine transaminase (ALT) and g-glutamyl
transferase (GGT) were determined by
enzymatic colorimetric assays (19).
Abdominal fat mass was measured by
computed tomography using a standard-
ized protocol at each clinical center. The
computed tomography scans were read
centrally at the Department of Radiology
Bio-Imaging Research Laboratory of the
University of Colorado Health Sciences
Center. Images obtained at the L4/L5
vertebral regions were used to determine
SAT and VAT. Bowel fat was subtracted
from the measurements of VAT (20,21).
Insulin sensitivity was determined
using a frequently sampled intravenous
glucose tolerance test (FSIGTT), with two
modifications to the original protocol
(22). First, insulin, instead of tolbuta-
mide, was injected to ensure adequate
levels of plasma insulin for accurate cal-
culation of insulin sensitivity across a
broad range of glucose tolerance (23).
Second, a reduced sampling protocol, us-
ing 12 instead of 30 samples, was used
because of the large number of partici-
pants (24). Insulin sensitivity, expressed
as SI, was calculated using minimal model
analysis (25). Insulin secretion was mea-
sured by acute insulin response (AIR), de-
fined as the average increase in plasma
insulin above the basal level in the first 8
min after infusing glucose (17). MCRIwas
calculated as the ratio of the insulin dose
over the incremental area under the curve
of insulin from 20 min to infinity (26)
using the following equation:
Clearance ðL=minÞ ¼ Dose 3 1000R∞
t¼20
ðInsðtÞ2 Insð0ÞÞ
;
where Dose is the amount of insulin
injected at 20 min, Ins(t) is the plasma
insulin concentration in standard units
(mU/mL) at each FSIGTT sampling point,
and Ins(0) is the fasting plasma insulin
concentration determined prior to the
FSIGTT glucose injection.
Demographic data (e.g., age, sex, and
ethnicity) and lifestyle factors (e.g., smok-
ing and alcohol consumption) were col-
lected on standardized questionnaires by
self-report (16). Anthropometric (e.g.,
height, weight, and waist circumference)
and blood pressure (BP) measurements
were taken according to standardized
procedures (16). Duplicate measure-
ments were made and averages were
used in the analyses.
Statistical analyses
We described the characteristics of par-
ticipants at baseline, stratified by thirds of
the distribution of MCRI, using medians
and interquartile ranges for continuous
variables and percentages for categorical
variables. We used generalized estimating
equations (GEE1) to test for differences in
continuous and categorical variables
across thirds of the MCRI, adjusting for
correlations within families.
Because of the skewed distribution,
we loge transformed MCRI and modeled
it as a continuous outcome. To minimize
the influence of the outlying observations
in variables with skewed distributions, we
loge transformed fasting insulin, SI+1,
GGT, ALT, and TGs and used a signed
square root transformation for AIR. We
used GEE1 linear regression to describe
the bivariate relationship of MCRI with
metabolic and anthropometric variables,
accounting for age, sex, and ethnicity. We
also used a multivariable GEE1 linear re-
gression to investigate the associations
between potential determinants and
MCRI. All continuous variables in the
GEE1 linear regressions were standard-
ized to a mean of 0 and an SD of 1. BMI
is removed from the multivariable GEE1
linear regression because it is highly cor-
related with SAT.
We used GEE1 logistic regression in a
multistage approach to explore the asso-
ciation between loge-transformed MCRI
as the continuous exposure variable and
incident diabetes ascertained in the 5-year
follow-up examination. Odds ratios
(ORs) per one-SD decrease in ln(MCRI)
were used to estimate relative risk and
were presented with 95% CIs. We in-
cluded covariates in the analyses if they
were of a priori clinical relevance or if they
were significantly associated with ln
(MCRI) in multivariable analyses shown
in Table 3. Covariates included age, sex,
ethnicity, smoking, alcohol consump-
tion, HDL cholesterol, SAT, VAT, and
AIR. We did not account for fasting insu-
lin and fasting glucose to avoid overad-
justment because these variables are
determined largely by insulin metabo-
lism, and they are on the causal pathway
for the development of type 2 diabetes.
We did not adjust for SI because of its
high correlation with MCRI. However,
in sensitivity analysis, we additionally in-
cluded SI in multivariable regression
models to determine if the MCRI-diabetes
association was mediated by a reduction
in insulin sensitivity. We tested for effect
modification between MCRI and sex, eth-
nicity, AIR, SI, VAT, and BMI on incident
diabetes. A P value,0.05 suggested a sig-
nificant interaction. All the statistical
analyses were performed using SAS ver-
sion 9.2 (SAS institute, Cary, NC).
RESULTSdAfter excluding individuals
with prevalent diabetes at baseline, and
those without measurements of MCRI,
the present analysis included 1,116 indi-
viduals who attended both baseline and
follow-up examinations. Characteristics of
the study population by thirds of MCRI
distribution at baseline are shown in Table
1. Participants had an average age of 40
years and 61% were women and 30%
were African Americans. In the 5-year
follow-up examinations, 71 participants
(6.4%) developed diabetes. Participants
with MCRI levels in the bottom third of
the baseline distribution were older and
were more likely to be African American.
They had significantly higher values for
BMI, waist circumference, VAT, SAT, fast-
ing insulin, AIR, GGT, ALT, systolic BP,
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and TGs, but lower values for SI and HDL
cholesterol.
As shown in Table 2, after adjusting
for age, sex, and ethnicity, MCRI
showed a positive association with SI
(b = 0.3726, P , 0.0001) and an inverse
association with fasting insulin (b =
20.3213, P , 0.0001). MCRI was in-
versely associated with all indexes of adi-
posity, including BMI, VAT, and SAT (b =
20.2944, 20.3171, and 20.2982, re-
spectively, all P , 0.0001). In addition,
higher levels of liver enzymes, including
GGT and ALT, were associated with re-
duced MCRI (b = 20.1411 and20.1214,
respectively, both P , 0.0001). MCRI
was positively associated with HDL cho-
lesterol (b = 0.2014, P , 0.0001) but
negatively associated with TGs (b =
20.3479, P , 0.0001). Other significant
inverse associations with MCRI included
AIR (b = 20.1847), fasting glucose (b =
20.1835), systolic BP (b =20.1206), non-
drinker (b = 20.1128), and nonsmoker
(b = 20.1521). SI and HDL cholesterol
were significant, independent, positive
correlates of MCRI, whereas VAT, SAT,
fasting insulin, fasting glucose, and AIR
were significant, independent, negative
correlates (Table 3).
In GEE1 multivariable logistic regres-
sion analyses, each one-SD decrease of ln
(MCRI) was associated with a higher risk
of incident diabetes after adjusting for
demographics, lifestyle factors, and HDL
cholesterol (OR 1.83 [95% CI 1.38–
2.42], P = 0.0010). Adjusting for VAT
and SAT attenuated the association to
nonsignificance (1.20 [0.84–1.70]).
However, the association was strength-
ened and became statistically significant
after additional adjustment of AIR (2.01
[1.30–3.10], P = 0.0064) (Fig. 1).
There was no significant interaction
between MCRI and sex, ethnicity, or AIR
on incident diabetes. However, we
observed a significant interaction of
MCRI with VAT on incident diabetes.
Stratified analyses suggested a stronger
inverse association of MCRI with incident
type 2 diabetes in individuals with lower
VAT (data not shown). In sensitivity
analyses to evaluate potential mediation
of this association by insulin sensitivity,
the inverse association between MCRI
and incident diabetes was attenuated to
nonsignificance when SI was additionally
included in the multivariable regression
models (OR 1.33 [95% CI 0.80–2.22]
per one-SD decrease in loge-transformed
MCRI).
CONCLUSIONSdIn this multiethnic
cohort of the IRAS Family Study, we
identified that decreased insulin clearance
was independently associated with ele-
vated plasma concentrations of fasting
insulin and fasting glucose, higher values
of AIR, SAT, and VAT, and decreased
levels of HDL cholesterol and SI. Our
finding of an independent inverse associ-
ation of insulin clearance with overall and
Table 1dCharacteristics of nondiabetic participants in the IRAS Family Study stratified by thirds of the distribution of MCRI at baseline
(n = 1,116)*
Thirds of MCRI distribution
1 2 3 P value**
n (%) 372 372 372
MCRI (L/min) 3.1 (2.5–3.5) 4.9 (4.4–5.3) 7.3 (6.6–8.6)
Age (years) 41.3 (31.9–49.9) 38.6 (30.1–49.1) 37.9 (29.2–46.7) 0.0047
Sex (% female) 57.5 62.6 62.1 0.3877
Ethnicity (%)
Hispanic American 64.5 64.3 80.1 0.0051
African American 35.5 35.7 19.9
Smoking (%)
Never 63.2 62.1 52.1
Former 22.6 17.2 15.9 0.0022
Current 14.2 20.7 32.0
Use of alcohol (%) 55.2 59.9 70.4 ,0.0001
BMI (kg/m2) 33.0 (29.3–37.1) 27.9 (25.2–30.5) 24.2 (21.7–26.4) ,0.0001
Waist circumference (cm) 99.4 (92.9–107.6) 87.7 (79.1–94.8) 77.5 (71.8–85.4) ,0.0001
VAT (cm2) 132.4 (95.8–169.2) 83.7 (56.1–121.3) 59.9 (39.1–92.3) ,0.0001
SAT (cm2) 427.7 (312.5–573.4) 307.4 (231.8–418.5) 224.5 (154.3–305.2) ,0.0001
Fasting insulin (pmol/L) 145.8 (111.1–187.5) 83.3 (62.5–104.2) 48.6 (34.7–69.5) ,0.0001
Fasting glucose (mmol/L) 5.4 (5.0–5.8) 5.1 (4.9–5.5) 5.0 (4.7–5.3) ,0.0001
SI (3 10
4/min/mU/mL) 0.7 (0.4–1.0) 1.6 (1.2–2.2) 3.1 (2.2–4.3) ,0.0001
AIR (pmol/mL/min) 950.4 (517.9–1,575.0) 660.5 (405.9–1,001.4) 456.8 (285.0–692.9) ,0.0001
GGT (IU/L) 33.0 (25.5–47.0) 26.0 (19.5–37.5) 23.0 (18.5–32.0) ,0.0001
ALT (IU/L) 9.0 (6.5–14.0) 7.5 (5.5–10.0) 7.3 (5.0–11.0) ,0.0001
Systolic BP (mmHg) 117.5 (110.0–128.0) 113.0 (104.0–124.0) 109.0 (103.0–118.0) ,0.0001
HDL cholesterol (mg/dL) 38.9 (34.0–44.1) 43.3 (38.0–50.3) 47.7 (41.5–55.6) ,0.0001
TGs (mmol/L) 1.3 (1.0–1.8) 1.1 (0.8–1.6) 0.9 (0.7–1.2) ,0.0001
IFG at baseline (%) 35.8 23.1 10.2 ,0.0001
Diabetes at follow-up (%) 11.0 5.1 3.0 0.0001
IFG, impaired fasting glucose. *Data presented are medians (interquartile ranges) or percentages. **P values are calculated from GEE1 models to account for family
structure, using continuous log-transformed MCRI.
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visceral adiposity, as indicated by higher
values of SAT and VAT, is consistent with
previous findings that hepatic clearance
of insulin is decreased in obese individu-
als (4,27–29). Compared with subcutane-
ous fat, visceral fat exerts a greater
influence in the impairment of insulin
clearance (5). These previous studies
used BMI and waist-to-hip ratio as surro-
gate measures of obesity and visceral ad-
iposity; whereas our study measured
body fat distribution using more detailed
procedures. Our findings extend the cur-
rent literature that states that directly
measured visceral and subcutaneous
adiposities are independently associated
with MCRI.
Elevated circulating and hepatic free
fatty acids (FFAs) from increased FFA flux
due to obesity, in particular visceral obe-
sity, may partially account for impaired
insulin clearance (30,31). In dogs, the
elevation of hepatic FFAs, a characteristic
of adiposity, results in peripheral hyper-
insulinemia with a corresponding decline
in insulin clearance (32). In humans, a
hyperglycemic clamp study demon-
strated that hyperinsulinemia caused by
elevated plasma FFAs was attributed pri-
marily to a significant decrease in insulin
clearance (33). FFAs may also provide a
link between the positive association that
we observed between HDL cholesterol
and insulin clearance. PPAR-g is ex-
pressed primarily in adipose tissues and
is implicated in HDL cholesterol metabo-
lism through its regulatory role in the re-
verse cholesterol transport pathway (34).
The Pro12Ala polymorphism of the
PPAR-g gene is associated with increased
insulin clearance and decreased insulin-
suppressed FFA concentrations, suggest-
ing that carriers of the Ala allele are able to
suppress lipolysis more efficiently (35).
Insulin sensitivity, insulin secretion,
and insulin clearance are dynamic phys-
iological processes for maintaining glu-
cose homeostasis. The current study
shows that insulin resistance (indicated
by increased fasting insulin and decreased
direct measures of SI) and insulin hyper-
secretion (expressed as increased AIR) are
independently associated with decreased
insulin clearance. In addition, hyperinsu-
linemic-euglycemic clamp studies dem-
onstrated that insulin clearance and
insulin secretion are independent deter-
minants of fasting insulin in individuals
with or without type 2 diabetes (36,37).
Decreased insulin clearance and increased
insulin secretion may represent a com-
pensatory response to obesity-induced
insulin resistance for maintaining glucose
tolerance. In a longitudinal study, dogs
fed a fat-enriched diet for 12 weeks
developed a sustained decrease in insulin
sensitivity. This was followed by a tran-
sient increase in AIR and a sustained de-
crease in insulin clearance to maintain
glucose levels in the normal range; there-
fore, decreased insulin clearance may
serve to preserveb-cell function in insulin
resistance states (13). However, we ob-
served that elevated fasting glucose was
independently associated with decreased
insulin clearance. The previous study (13)
in dogs modified the short-term dietary
fat intake to induce adiposity so as to eval-
uate the concurrent compensation for in-
sulin resistance. No change in glucose
level was noted at the end of the 12-
week experiment. Of note is that these
lean dogs had normal insulin sensitivity
before the experimental protocol to
Table 2dBivariate determinants of ln(MCRI) in the IRAS Family Study, adjusted for age,
sex, and ethnicity
Estimate* SE P value
Smoking
Never 20.1521 0.0409 0.0021
Former 20.1396 0.0519
Alcohol (nondrinker) 20.1128 0.0275 ,0.0001
BMI 20.2944 0.0139 ,0.0001
VAT 20.3171 0.0154 ,0.0001
SAT 20.2982 0.0145 ,0.0001
Fasting insulin# 20.3213 0.0187 ,0.0001
Fasting glucose 20.1835 0.0137 ,0.0001
SI# 0.3726 0.0117 ,0.0001
AIR^ 20.1847 0.0152 ,0.0001
GGT# 20.1411 0.0164 ,0.0001
ALT# 20.1214 0.0167 ,0.0001
Systolic BP 20.1206 0.0161 ,0.0001
HDL cholesterol 0.2014 0.0155 ,0.0001
TGs# 20.1670 0.0146 ,0.0001
*All continuous variables are standardized to a mean of 0 and SD of 1. #Natural log transformation. ^Signed
square root transformation.
Table 3dMultivariable determinants of ln(MCRI) in the IRAS Family Study
Estimate* SE P value
Age 0.0028 0.0097 0.2638
Sex (male) 0.0053 0.0189 0.0966
Ethnicity (Hispanic) 0.0329 0.0226 0.0889
Smoking
Never 20.0223 0.0197 0.2114
Former 0.0087 0.0223
Alcohol (nondrinker) 20.0081 0.0174 0.4372
VAT 20.0315 0.0126 0.0006
SAT 20.0065 0.0172 ,0.0001
Fasting insulin# 20.1172 0.0155 ,0.0001
Fasting glucose 20.0201 0.0102 0.0330
SI# 0.1947 0.0149 ,0.0001
AIR^ 20.0724 0.0090 ,0.0001
GGT# 20.0134 0.0093 0.1461
ALT# 0.0021 0.0096 0.8456
Systolic BP 0.0123 0.0083 0.2211
HDL cholesterol 0.0239 0.0081 0.0056
TGs# 0.0051 0.0089 0.5232
BMI is removed from this analysis because of high collinearity with SAT. *All continuous variables are
standardized to a mean of 0 and SD of 1. #Natural log transformation. ^Signed square root transformation.
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induce insulin resistance; hence, the re-
sults represented an early development
of insulin resistance. As insulin resistance
progresses, fasting glucose is expected to
increase to reflect the deterioration of the
insulin compensatory response. There-
fore, the difference in findings between
our study and the previous study (13)
could be related to the time frame and
severity of insulin resistance.
Ethnic differences exist in the mech-
anisms of adaptation to insulin resistance.
African American adults and children,
compared with their Hispanic and Cau-
casian counterparts, have lower insulin
clearance and greater AIR as a conse-
quence of decreased insulin sensitivity
(38,39). These observations may stem
from the differences in obesity-related
phenotypes between these ethnic groups,
such as accumulation of fat depots and
level of insulin-like growth factor-1 (40).
We observed that African Americans have
lower values of MCRI than Hispanics;
however, ethnicity was not indepen-
dently associated with MCRI in the mul-
tivariable regression models.
In a prospective analysis, we showed
that decreased MCRI at baseline was
associated with incident diabetes after
adjusting for demographics, lifestyle fac-
tors, and HDL cholesterol. Additional
adjustment for SAT and VAT attenu-
ated the association to nonsignificance.
However, we observed an apparent in-
verse association between MCRI and in-
cident diabetes after further adjusting for
AIR. We also observed a stronger inverse
association of MCRI with incident diabe-
tes in individuals with less VAT. To our
knowledge, no previous study has shown
these associations. The strong inverse re-
lationship of obesity and visceral adiposity
with MCRI, as discussed earlier, provides a
basis for the confounding effect of SAT and
VAT on the association between MCRI and
incident diabetes. We have previously re-
ported in this cohort a significant inverse
association of SAT and VAT with SI and
AIR (20), which in turn increased the risk
of incident diabetes (17).
Since SI is highly correlated with
MCRI, we did not adjust for insulin sen-
sitivity in the main models due to multi-
collinearity. However, it is not surprising
to observe that additionally adjusting for
SI attenuated the MCRI-diabetes associa-
tion to nonsignificance in sensitivity
analyses due to their close relationships.
This finding suggests that SI may, in part,
mediate the link between MCRI and
diabetes.
Including AIR in the multivariable
regression models to investigate the asso-
ciation between MCRI and incident di-
abetes may represent an overadjustment
as derangement of these traits are patho-
physiological mechanisms on the causal
pathway of type 2 diabetes. However,
adjusting for AIR could help to elucidate
whether MCRI predicts incident diabetes
independent of it. Of note is that our data
onMCRI and AIR were determined at one
particular point in time, whichmay not be
sufficient to illustrate the complex inter-
play of these metabolic traits in a cohort of
individuals with different stages of insulin
resistance and compensatory mecha-
nisms in the time course of their associ-
atedmetabolic changes. Our observations
highlight the need for longitudinal studies
in humans to illustrate the progression of
insulin resistance and its corresponding
physiological responses.
The particular strengths of the IRAS
Family Study include the well-character-
ized prospective cohort of Hispanics and
African Americans, two ethnic groups
that are at high risk of developing di-
abetes, and its detailed measurements of
insulin sensitivity, insulin secretion, in-
sulin clearance, and adiposity. Neverthe-
less, several potential limitations should
also be considered. Without oral glucose
tolerance tests, some individuals with
elevated postprandial glucose levels may
have been misclassified as not having
diabetes. Finally, results of this study
may not be generalizable to other popu-
lations. Our findings have important clin-
ical implications. We observed that VAT,
SAT, and HDL cholesterol are indepen-
dently associated with MCRI. Since adi-
posity and lipids are modifiable, lifestyle
modification and weight reduction
should continue to be emphasized. In
addition, these results support MCRI as a
potential therapeutic target in preventing
diabetes.
In conclusion, in this multiethnic
cohort of Hispanic and African American
adults, factors that are independently
associated with decreased insulin clear-
ance include elevated fasting insulin, fast-
ing glucose, AIR, SAT, and VAT, as well as
decreased HDL cholesterol and SI. In ad-
dition, we demonstrated that lower insu-
lin clearance predicted the development
of type 2 diabetes, independent of demo-
graphics, lifestyle factors, HDL choles-
terol, indexes of overall and visceral
adiposity, and insulin secretion.
AcknowledgmentsdC.C.L. is supported by a
postdoctoral research fellowship from the
Banting and Best Diabetes Centre (University
of Toronto, Ontario, Canada). A.J.H. holds
a Tier II Canada Research Chair in Diabe-
tes Epidemiology. M.O.G. is supported by
Figure 1dAssociation of MCRI with incident type 2 diabetes for each one-SD decrease in log-
transformed MCRI at baseline in the IRAS Family Study. Model 1, adjusted for age, sex, and
ethnicity; model 2, model 1 + smoking and alcohol consumption; model 3, model 2 + HDL cho-
lesterol; model 4, model 3 + SAT and VAT; model 5, model 4 + AIR (signed square root trans-
formation).
care.diabetesjournals.org DIABETES CARE, VOLUME 36, APRIL 2013 905
Lee and Associates
National Institutes of Health Grant DK-079888.
The IRAS Family Study is supported by grants
from the National Institutes of Health (HL-
60944-02, HL-61210-02, HL-61019-02, HL-
60894, and HL-60931-02).
No potential conflicts of interest relevant to
this article were reported.
C.C.L. wrote, reviewed, and edited the
manuscript and contributed to discussion.
S.M.H. and L.E.W. researched data, reviewed
and edited the manuscript, and contributed to
discussion. C.L., J.M.N., R.N.B., D.S., A.M.A.,
J.I.R., M.O.G., and A.J.H. reviewed and edited
the manuscript and contributed to discussion.
A.J.H. is the guarantor of this work and, as
such, had full access to all the data in the study
and takes responsibility for the integrity of the
data and the accuracy of the data analysis.
Parts of this study were presented at the
71st Scientific Sessions of the American Di-
abetes Association, San Diego, California, 24–
28 June 2010.
References
1. Duckworth WC, Bennett RG, Hamel FG.
The significance of intracellular insulin to
insulin action. J Investig Med 1997;45:
20–27
2. Duckworth WC, Bennett RG, Hamel FG.
Insulin degradation: progress and poten-
tial. Endocr Rev 1998;19:608–624
3. Bonora E, Zavaroni I, Coscelli C, Butturini
U. Decreased hepatic insulin extraction in
subjects with mild glucose intolerance.
Metabolism 1983;32:438–446
4. Meistas MT, Margolis S, Kowarski AA.
Hyperinsulinemia of obesity is due to
decreased clearance of insulin. Am J
Physiol 1983;245:E155–E159
5. Peiris AN,Mueller RA, SmithGA, StruveMF,
Kissebah AH. Splanchnic insulin metabo-
lism in obesity. Influence of body fat distri-
bution. J Clin Invest 1986;78:1648–1657
6. Salvatore T, Cozzolino D, Giunta R,
Giugliano D, Torella R, D’Onofrio F. De-
creased insulin clearance as a feature of
essential hypertension. J Clin Endocrinol
Metab 1992;74:144–149
7. Iwasaki Y, Ohkubo A, Kajinuma H,
Akanuma Y, Kosaka K. Degradation and
secretion of insulin in hepatic cirrhosis.
J Clin Endocrinol Metab 1978;47:774–779
8. Goto T, Onuma T, Takebe K, Kral JG. The
influence of fatty liver on insulin clearance
and insulin resistance in non-diabetic
Japanese subjects. Int J Obes Relat Metab
Disord 1995;19:841–845
9. Flier JS, Minaker KL, Landsberg L, Young
JB, Pallotta J, Rowe JW. Impaired in vivo
insulin clearance in patients with severe
target-cell resistance to insulin. Diabetes
1982;31:132–135
10. Jones CN, Abbasi F, CarantoniM, Polonsky
KS, Reaven GM. Roles of insulin resistance
and obesity in regulation of plasma insulin
concentrations. Am J Physiol Endocrinol
Metab 2000;278:E501–E508
11. Haffner SM, Stern MP, Watanabe RM,
Bergman RN. Relationship of insulin
clearance and secretion to insulin sen-
sitivity in non-diabetic Mexican Ameri-
cans. Eur J Clin Invest 1992;22:147–
153
12. Højlund K, Wojtaszewski JF, Birk J,
Hansen BF, Vestergaard H, Beck-
Nielsen H. Partial rescue of in vivo in-
sulin signalling in skeletal muscle by
impaired insulin clearance in heterozy-
gous carriers of a mutation in the insulin
receptor gene. Diabetologia 2006;49:
1827–1837
13. Mittelman SD, Van Citters GW, Kim SP,
et al. Longitudinal compensation for fat-
induced insulin resistance includes re-
duced insulin clearance and enhanced
beta-cell response. Diabetes 2000;49:
2116–2125
14. Kim SP, Ellmerer M, Kirkman EL,
Bergman RN. Beta-cell “rest” accompanies
reduced first-pass hepatic insulin extrac-
tion in the insulin-resistant, fat-fed canine
model. Am J Physiol Endocrinol Metab
2007;292:E1581–E1589
15. Goodarzi MO, Taylor KD, Guo X, et al.
Variation in the gene for muscle-specific
AMP deaminase is associated with insulin
clearance, a highly heritable trait. Diabetes
2005;54:1222–1227
16. Henkin L, Bergman RN, Bowden DW,
et al. Genetic epidemiology of insulin re-
sistance and visceral adiposity. The IRAS
Family Study design and methods. Ann
Epidemiol 2003;13:211–217
17. Hanley AJ, Wagenknecht LE, Norris JM,
et al. Insulin resistance, beta cell dys-
function and visceral adiposity as pre-
dictors of incident diabetes: the Insulin
Resistance Atherosclerosis Study (IRAS)
Family study. Diabetologia 2009;52:
2079–2086
18. Herbert V, Lau KS, Gottlieb CW, Bleicher
SJ. Coated charcoal immunoassay of in-
sulin. J Clin Endocrinol Metab 1965;25:
1375–1384
19. Wagenknecht LE, Palmer ND, Bowden
DW, et al. Association of PNPLA3 with
non-alcoholic fatty liver disease in a mi-
nority cohort: the Insulin Resistance
Atherosclerosis Family Study. Liver Int
2011;31:412–416
20. Wagenknecht LE, Langefeld CD,
Scherzinger AL, et al. Insulin sensitivity,
insulin secretion, and abdominal fat: The
Insulin Resistance Atherosclerosis Study
(IRAS) Family Study. Diabetes 2003;52:
2490–2496
21. Hairston KG, Vitolins MZ, Norris JM,
Anderson AM, Hanley AJ, Wagenknecht
LE. Lifestyle factors and 5-year abdominal
fat accumulation in a minority cohort: the
IRAS Family Study. Obesity (Silver Spring)
2012;20:421–427
22. Bergman RN, Finegood DT, Ader M. As-
sessment of insulin sensitivity in vivo.
Endocr Rev 1985;6:45–86
23. Welch S, Gebhart SSP, Bergman RN,
Phillips LS. Minimal model analysis of
intravenous glucose tolerance test-de-
rived insulin sensitivity in diabetic sub-
jects. J Clin Endocrinol Metab 1990;71:
1508–1518
24. Steil GM, Volund A, Kahn SE, Bergman
RN. Reduced sample number for calcula-
tion of insulin sensitivity and glucose ef-
fectiveness from the minimal model.
Suitability for use in population studies.
Diabetes 1993;42:250–256
25. Pacini G, Bergman RN. MINMOD:
a computer program to calculate insu-
lin sensitivity and pancreatic responsivity
from the frequently sampled intravenous
glucose tolerance test. Comput Methods
Programs Biomed 1986;23:113–122
26. Polonsky KS, Pugh W, Jaspan JB, et al.
C-peptide and insulin secretion. Re-
lationship between peripheral concen-
trations of C-peptide and insulin and their
secretion rates in the dog. J Clin Invest
1984;74:1821–1829
27. Polonsky KS, Given BD, Hirsch L, et al.
Quantitative study of insulin secretion
and clearance in normal and obese sub-
jects. J Clin Invest 1988;81:435–441
28. Rossell R, Gomis R, Casamitjana R, Segura
R, Vilardell E, Rivera F. Reduced hepatic
insulin extraction in obesity: relationship
with plasma insulin levels. J Clin Endo-
crinol Metab 1983;56:608–611
29. Faber OK, Christensen K, Kehlet H,
Madsbad S, Binder C. Decreased insulin
removal contributes to hyperinsulinemia
in obesity. J Clin Endocrinol Metab 1981;
53:618–621
30. Lewis GF, Carpentier A, Adeli K, Giacca A.
Disordered fat storage and mobilization in
the pathogenesis of insulin resistance and
type 2 diabetes. Endocr Rev 2002;23:
201–229
31. Wiesenthal SR, Sandhu H, McCall RH,
et al. Free fatty acids impair hepatic in-
sulin extraction in vivo. Diabetes 1999;48:
766–774
32. Yoshii H, Lam TK, Gupta N, et al. Effects
of portal free fatty acid elevation on in-
sulin clearance and hepatic glucose flux.
Am J Physiol Endocrinol Metab 2006;
290:E1089–E1097
33. Balent B, Goswami G, Goodloe G, et al.
Acute elevation of NEFA causes hyper-
insulinemia without effect on insulin
secretion rate in healthy human sub-
jects. Ann N Y Acad Sci 2002;967:535–
543
34. Chinetti G, Lestavel S, Bocher V, et al.
PPAR-alpha and PPAR-gamma activators
induce cholesterol removal from human
macrophage foam cells through stimula-
tion of the ABCA1 pathway. Nat Med
2001;7:53–58
35. Tschritter O, Fritsche A, Stefan N, et al.
Increased insulin clearance in peroxisome
proliferator-activated receptor gamma2
Pro12Ala. Metabolism 2003;52:778–783
906 DIABETES CARE, VOLUME 36, APRIL 2013 care.diabetesjournals.org
Insulin clearance and incident diabetes
36. Goodarzi MO, Cui J, Chen YD, Hsueh
WA, Guo X, Rotter JI. Fasting insulin re-
flects heterogeneous physiological pro-
cesses: role of insulin clearance. Am J
Physiol Endocrinol Metab 2011;301:
E402–E408
37. Kotronen A, Juurinen L, Tiikkainen M,
Vehkavaara S, Yki-Järvinen H. Increased
liver fat, impaired insulin clearance, and
hepatic and adipose tissue insulin re-
sistance in type 2 diabetes. Gastroenter-
ology 2008;135:122–130
38. Osei K, Schuster DP. Ethnic differences in
secretion, sensitivity, and hepatic extrac-
tion of insulin in black and white Ameri-
cans. Diabet Med 1994;11:755–762
39. Weiss R, Dziura JD, Burgert TS, Taksali
SE, Tamborlane WV, Caprio S. Ethnic
differences in beta cell adaptation to in-
sulin resistance in obese children and
adolescents. Diabetologia 2006;49:571–
579
40. Goran MI. Ethnic-specific pathways
to obesity-related disease: the Hispanic
vs. African-American paradox. Obe-
sity (Silver Spring) 2008;16:2561–
2565
care.diabetesjournals.org DIABETES CARE, VOLUME 36, APRIL 2013 907
Lee and Associates
